Introducing Citeline’s TrialScope Disclose: Core Data
Clinical Trial Disclosure Solution Harmonizes Data Across Multiple Regions, Registries
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Submitting clinical trial disclosures across different regions can be a fragmented, cumbersome process. Citeline’s new TrialScope Disclose: Core Data is a unified registry submission platform that helps consolidate and streamline clinical trial disclosure processes.
TrialScope Disclose: Core Data features the required global data fields in a single form, allowing for one-time disclosure across multiple registries, including ClinicalTrials.gov, CTIS and jRCT, with more registries being added in the near future. Core Data eliminates duplicate data entry across registries, streamlining the review/approval process for senior staff and ensuring consistency and efficiency, while its built-in validations and compliance checks reduce risks.
“Managing clinical trial disclosures across multiple registries is often done in a piecemeal fashion, leaving the process open to errors and inconsistencies that can lead to noncompliance,” says David Laky, General Manager, Clinical & Regulatory, Citeline. “TrialScope Disclose: Core Data allows for approval and submission from a single source of truth, helping to simplify, harmonize and accelerate the clinical trial disclosure process.”
TrialScope Disclose has been the leader in helping clinical trial sponsors prepare their studies for public disclosure for over a decade. With the addition of the Core Data platform, TrialScope Disclose continues to provide cutting-edge disclosure technology to enable seamless regulatory compliance.
Learn more about Citeline’s TrialScope Disclose.
About Citeline
Citeline, a Norstella company, powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial, and regulatory-related decisions and create real-world opportunities for growth.
Citeline’s global teams of analysts, journalists, and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X.
Citeline PR contact:
Diffusion PR for Citeline
citeline@diffusionpr.com
(213) 318-4500
标签:
热点文章
济宁高新区接庄街道儒学讲堂开展“弘扬中华优秀传统文化”主题宣讲活动
晴天科技冲击“中国户用光伏第一股”:业务模式存争议,融资租赁数据打架|清流·IPO
扎克伯格正在夏威夷建立末日掩体:拥有独立能源、食物供应系统
济宁高新区柳行街道府东社区开展“黄河大集”暨“寒冬送温暖 姜茶暖人心”活动
公募2023盘点:整体表现惨淡 股票ETF持续吸金
李斌直播连麦何小鹏:我要买X9的话得便宜点啊
济宁高新区接庄街道开展“强国有我 学无止境”学习强国主题宣讲活动
2024网易经济学家年会即将召开,李毅中、尹中卿、贺铿、江小涓、龙永图等嘉宾出席